≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback

Nutritional marasmus

DOID EFO Endpoint Browser PheWeb

E4_MARASMUS

marasmus: The lack of sufficient energy or protein to meet the body's metabolic demands, as a result of either an inadequate dietary intake of protein, intake of poor quality dietary protein, increased demands due to disease, or increased nutrient losses.

Suggest a new description

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

None

519870

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — E41
  • Hospital discharge: ICD-9 — 261
  • Cause of death: ICD-10 — E41
  • Cause of death: ICD-9 — 261

2 out of 7 registries used, show all original rules.

74

4. Check minimum number of events

None

74

5. Include endpoints

None

74

6. Filter based on genotype QC (FinnGen only)

70

Control definitions (FinnGen only)

Control exclude
E4_MALNUTRITION

Extra metadata

Level in the ICD hierarchy
3
First used in FinnGen datafreeze
DF2
Parent code in ICD-10
E40-E46
Name in latin
Malnutritio gravis ex deficientia energetica (marasmus nutritionalis)

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

All Female Male
Number of individuals
Whole population 989 547 434
Only index persons 714 397 317
Unadjusted period prevalence (%)
Whole population 0.01 0.02 0.01
Only index persons 0.01 0.01 0.01
Median age at first event (years)
Whole population 63.82 66.09 60.76
Only index persons 59.82 61.49 57.73

-FinnGen-

Key figures

All Female Male
Number of individuals 70 44 26
Unadjusted period prevalence (%) 0.01 0.02 0.01
Median age at first event (years) 55.86 51.92 62.54

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
74
Matched controls
740
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
E41
ICD-10 Finland
Nutritional marasmus
+∞
98.5
71
*
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
5.7
10.9
27
68
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
4.4
9.2
37
136
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
3.6
6.8
40
183
N05BA01
ATC
diazepam; systemic, rectal
4.7
6.1
16
41

TimeCodeWAS

↥

TODO / Current known limitations:

  • Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
  • Legend / how to read the glyphs.
  • Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
  • Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
  • Download CSV.
  • No filters and sorters.
  • Limited amount of endpoints (~400) having TimeCodeWAS data.
  • Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
Albumin [Mass/volume] in Serum or Plasma
1751-7 [3024561]
1.2e+00
1.5e+00
2.5e+00
—
3.7e+00
—
—
cases:29.58%
controls:11.13%
cases:21.13%
controls:5.49%
cases:15.49%
controls:1.41%
—
—
cases:23.33%
controls:0.71%
—
—
—
—
21
79
50
631
15
39
56
671
11
10
60
700
—
14
5
46
702
—
—
Psychiatry
26 [38004469]
1.5e+00
2.2e+00
2.1e+00
—
2.9e+00
—
—
cases:18.31%
controls:4.79%
cases:18.31%
controls:2.39%
cases:9.86%
controls:1.27%
—
—
cases:15.00%
controls:0.99%
—
—
—
—
13
34
58
676
13
17
58
693
7
9
64
701
—
9
7
51
700
—
—
Emergency Room Visit
ER [9203]
8.4e-01
1.9e+00
3.1e+00
1.0e+50
2.5e+00
—
—
cases:53.52%
controls:33.10%
cases:43.66%
controls:10.85%
cases:21.13%
controls:1.13%
cases:19.72%
controls:0.00%
cases:18.33%
controls:1.84%
—
—
—
—
38
235
33
475
31
77
40
633
15
8
56
702
14
0
57
710
11
13
49
694
—
—
Calcium.ionized [Moles/volume] in Serum or Plasma
1995-0 [3021347]
4.9e-01
1.8e+00
3.3e+00
—
3.1e+00
—
—
cases:21.13%
controls:14.08%
cases:28.17%
controls:5.92%
cases:18.31%
controls:0.85%
—
—
cases:18.33%
controls:0.99%
—
—
—
—
15
100
56
610
20
42
51
668
13
6
58
704
—
11
7
49
700
—
—
Internal Medicine
11 [38004456]
8.0e-01
1.7e+00
2.9e+00
1.0e+50
3.1e+00
—
—
cases:35.21%
controls:19.58%
cases:32.39%
controls:7.75%
cases:15.49%
controls:0.99%
cases:35.21%
controls:0.00%
cases:25.00%
controls:1.41%
—
—
—
—
25
139
46
571
23
55
48
655
11
7
60
703
25
0
46
710
15
10
45
697
—
—
Inpatient Hospital
21 [8717]
9.6e-01
1.7e+00
2.6e+00
1.0e+50
2.6e+00
—
—
cases:52.11%
controls:29.44%
cases:35.21%
controls:9.30%
cases:18.31%
controls:1.69%
cases:25.35%
controls:0.00%
cases:13.33%
controls:1.13%
—
—
—
—
37
209
34
501
25
66
46
644
13
12
58
698
18
0
53
710
8
8
52
699
—
—
Bilirubin.total [Moles/volume] in Serum or Plasma
14631-6 [3006140]
1.0e+00
1.6e+00
2.1e+00
—
3.0e+00
—
—
cases:28.17%
controls:12.11%
cases:22.54%
controls:5.49%
cases:12.68%
controls:1.69%
—
—
cases:16.67%
controls:0.99%
—
—
—
—
20
86
51
624
16
39
55
671
9
12
62
698
—
10
7
50
700
—
—
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
19072-8 [3016431]
3.7e-01
1.8e+00
2.6e+00
—
3.1e+00
—
—
cases:21.13%
controls:15.63%
cases:29.58%
controls:6.48%
cases:16.90%
controls:1.41%
—
—
cases:18.33%
controls:0.99%
—
—
—
—
15
111
56
599
21
46
50
664
12
10
59
700
—
11
7
49
700
—
—
INR in Blood by Coagulation assay
34714-6 [3032080]
8.8e-01
1.8e+00
2.1e+00
—
2.7e+00
—
—
cases:23.94%
controls:11.55%
cases:19.72%
controls:3.94%
cases:12.68%
controls:1.69%
—
—
cases:15.00%
controls:1.13%
—
—
—
—
17
82
54
628
14
28
57
682
9
12
62
698
—
9
8
51
699
—
—
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
6768-6 [3035995]
6.7e-01
1.1e+00
2.3e+00
—
3.0e+00
—
—
cases:36.62%
controls:22.82%
cases:29.58%
controls:12.25%
cases:21.13%
controls:2.68%
—
—
cases:20.00%
controls:1.27%
—
—
—
—
26
162
45
548
21
87
50
623
15
19
56
691
—
12
9
48
698
—
—
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
2.3e-01
9.1e-01
2.3e+00
—
2.7e+00
—
—
cases:40.85%
controls:35.35%
cases:36.62%
controls:18.87%
cases:23.94%
controls:2.96%
—
—
cases:28.33%
controls:2.55%
—
—
—
—
29
251
42
459
26
134
45
576
17
21
54
689
—
17
18
43
689
—
—
Neutrophils [#/volume] in Blood by Automated count
751-8 [3013650]
7.1e-01
1.1e+00
1.6e+00
—
3.0e+00
—
—
cases:32.39%
controls:19.01%
cases:23.94%
controls:9.72%
cases:12.68%
controls:2.96%
—
—
cases:18.33%
controls:1.13%
—
—
—
—
23
135
48
575
17
69
54
641
9
21
62
689
—
11
8
49
699
—
—
Normoblasts [#/volume] in Blood
715-3 [3021589]
7.0e-01
6.5e-01
2.2e+00
—
3.0e+00
—
—
cases:23.94%
controls:13.52%
cases:16.90%
controls:9.58%
cases:16.90%
controls:2.25%
—
—
cases:18.33%
controls:1.13%
—
—
—
—
17
96
54
614
12
68
59
642
12
16
59
694
—
11
8
49
699
—
—
Basophils [#/volume] in Blood
26444-0 [3006315]
7.0e-01
8.1e-01
2.0e+00
—
2.7e+00
—
—
cases:28.17%
controls:16.34%
cases:16.90%
controls:8.31%
cases:14.08%
controls:2.25%
—
—
cases:11.67%
controls:0.85%
—
—
—
—
20
116
51
594
12
59
59
651
10
16
61
694
—
7
6
53
701
—
—
Lymphocytes [#/volume] in Blood
26474-7 [3019198]
6.6e-01
7.4e-01
2.0e+00
—
2.7e+00
—
—
cases:28.17%
controls:16.90%
cases:16.90%
controls:8.87%
cases:14.08%
controls:2.25%
—
—
cases:11.67%
controls:0.85%
—
—
—
—
20
120
51
590
12
63
59
647
10
16
61
694
—
7
6
53
701
—
—
Monocytes [#/volume] in Blood
26484-6 [3001604]
7.0e-01
8.1e-01
2.0e+00
—
2.7e+00
—
—
cases:28.17%
controls:16.34%
cases:16.90%
controls:8.31%
cases:14.08%
controls:2.25%
—
—
cases:11.67%
controls:0.85%
—
—
—
—
20
116
51
594
12
59
59
651
10
16
61
694
—
7
6
53
701
—
—
Neutrophils/Leukocytes in Blood
26511-6 [3018010]
5.8e-01
6.3e-01
2.1e+00
—
2.4e+00
—
—
cases:25.35%
controls:15.92%
cases:14.08%
controls:8.03%
cases:14.08%
controls:1.97%
—
—
cases:10.00%
controls:0.99%
—
—
—
—
18
113
53
597
10
57
61
653
10
14
61
696
—
6
7
54
700
—
—
Eosinophils/Leukocytes in Blood
26450-7 [3006504]
6.0e-01
6.7e-01
2.0e+00
—
2.4e+00
—
—
cases:25.35%
controls:15.77%
cases:14.08%
controls:7.75%
cases:14.08%
controls:2.11%
—
—
cases:10.00%
controls:0.99%
—
—
—
—
18
112
53
598
10
55
61
655
10
15
61
695
—
6
7
54
700
—
—
Lymphocytes/Leukocytes in Blood
26478-8 [3002030]
5.6e-01
6.3e-01
2.0e+00
—
2.4e+00
—
—
cases:25.35%
controls:16.20%
cases:14.08%
controls:8.03%
cases:14.08%
controls:2.11%
—
—
cases:10.00%
controls:0.99%
—
—
—
—
18
115
53
595
10
57
61
653
10
15
61
695
—
6
7
54
700
—
—
Monocytes/Leukocytes in Blood
26485-3 [3019069]
6.0e-01
6.7e-01
2.0e+00
—
2.4e+00
—
—
cases:25.35%
controls:15.77%
cases:14.08%
controls:7.75%
cases:14.08%
controls:2.11%
—
—
cases:10.00%
controls:0.99%
—
—
—
—
18
112
53
598
10
55
61
655
10
15
61
695
—
6
7
54
700
—
—
Basophils/Leukocytes in Blood
30180-4 [3022096]
6.0e-01
6.7e-01
2.0e+00
—
2.4e+00
—
—
cases:25.35%
controls:15.77%
cases:14.08%
controls:7.75%
cases:14.08%
controls:2.11%
—
—
cases:10.00%
controls:0.99%
—
—
—
—
18
112
53
598
10
55
61
655
10
15
61
695
—
6
7
54
700
—
—
Eosinophils [#/volume] in Blood
26449-9 [3013115]
7.9e-01
8.9e-01
1.8e+00
—
2.6e+00
—
—
cases:30.99%
controls:16.90%
cases:18.31%
controls:8.45%
cases:14.08%
controls:2.54%
—
—
cases:11.67%
controls:0.99%
—
—
—
—
22
120
49
590
13
60
58
650
10
18
61
692
—
7
7
53
700
—
—
Differential panel, method unspecified - Blood
69738-3 [42870588]
8.4e-01
9.4e-01
1.8e+00
—
2.6e+00
—
—
cases:22.54%
controls:11.13%
cases:12.68%
controls:5.35%
cases:11.27%
controls:1.97%
—
—
cases:10.00%
controls:0.85%
—
—
—
—
16
79
55
631
9
38
62
672
8
14
63
696
—
6
6
54
701
—
—
Glucose [Moles/volume] in Serum or Plasma
14749-6 [3013826]
6.2e-01
1.6e+00
—
1.0e+50
2.7e+00
—
—
cases:26.76%
controls:16.48%
cases:26.76%
controls:6.76%
—
—
cases:8.45%
controls:0.00%
cases:11.67%
controls:0.85%
—
—
—
—
19
117
52
593
19
48
52
662
—
6
0
65
710
7
6
53
701
—
—
Sodium [Moles/volume] in Serum or Plasma
2951-2 [3019550]
2.9e-02
6.2e-01
2.0e+00
—
2.3e+00
—
—
cases:40.85%
controls:40.14%
cases:42.25%
controls:28.17%
cases:28.17%
controls:4.93%
—
—
cases:28.33%
controls:3.82%
—
—
—
—
29
285
42
425
30
200
41
510
20
35
51
675
—
17
27
43
680
—
—
Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]
8.1e-02
6.2e-01
2.0e+00
—
2.2e+00
—
—
cases:42.25%
controls:40.28%
cases:42.25%
controls:28.17%
cases:28.17%
controls:4.79%
—
—
cases:28.33%
controls:4.10%
—
—
—
—
30
286
41
424
30
200
41
510
20
34
51
676
—
17
29
43
678
—
—
Esophagoscopy, gastroscopy and duodenoscopy
UJD10 [2001304788]
1.7e+00
2.5e+00
—
—
—
—
—
cases:18.31%
controls:4.08%
cases:9.86%
controls:0.85%
—
—
—
—
—
—
—
—
—
—
13
29
58
681
7
6
64
704
—
—
—
—
—
Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1742-6 [3006923]
3.5e-02
2.8e-01
1.9e+00
—
2.2e+00
—
—
cases:40.85%
controls:40.00%
cases:32.39%
controls:26.62%
cases:26.76%
controls:5.21%
—
—
cases:25.00%
controls:3.68%
—
—
—
—
29
284
42
426
23
189
48
521
19
37
52
673
—
15
26
45
681
—
—
Nitrite [Presence] in Urine by Test strip
5802-4 [3021601]
4.5e-01
1.5e+00
—
—
2.6e+00
—
—
cases:15.49%
controls:10.42%
cases:18.31%
controls:4.93%
—
—
—
—
cases:10.00%
controls:0.85%
—
—
—
—
11
74
60
636
13
35
58
675
—
—
6
6
54
701
—
—
Glucose [Presence] in Urine by Test strip
25428-4 [3009261]
3.8e-01
1.5e+00
—
—
2.6e+00
—
—
cases:15.49%
controls:11.13%
cases:18.31%
controls:4.93%
—
—
—
—
cases:10.00%
controls:0.85%
—
—
—
—
11
79
60
631
13
35
58
675
—
—
6
6
54
701
—
—
Ketones [Presence] in Urine by Test strip
2514-8 [3035350]
4.0e-01
1.5e+00
—
—
2.6e+00
—
—
cases:15.49%
controls:10.99%
cases:18.31%
controls:4.93%
—
—
—
—
cases:10.00%
controls:0.85%
—
—
—
—
11
78
60
632
13
35
58
675
—
—
6
6
54
701
—
—
Bacteria [#/volume] in Urine by Automated count
51480-2 [3031040]
1.7e-01
1.6e+00
2.2e+00
1.0e+50
2.2e+00
—
—
cases:21.13%
controls:18.45%
cases:28.17%
controls:7.04%
cases:8.45%
controls:0.99%
cases:7.04%
controls:0.00%
cases:8.33%
controls:0.99%
—
—
—
—
15
131
56
579
20
50
51
660
6
7
65
703
5
0
66
710
5
7
55
700
—
—
Office Visit
OMOP4822458 [581477]
1.1e+00
2.6e+00
—
—
—
—
—
cases:26.76%
controls:10.42%
cases:26.76%
controls:2.68%
—
—
—
—
—
—
—
—
—
—
19
74
52
636
19
19
52
691
—
—
—
—
—
Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]
1.1e-01
3.7e-01
1.8e+00
1.0e+50
1.9e+00
—
—
cases:45.07%
controls:42.25%
cases:39.44%
controls:30.99%
cases:29.58%
controls:6.76%
cases:22.54%
controls:0.00%
cases:28.33%
controls:5.37%
—
—
—
—
32
300
39
410
28
220
43
490
21
48
50
662
16
0
55
710
17
38
43
669
—
—
25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Moles/volume] in Serum or Plasma
68438-1 [40771025]
4.9e-01
1.3e+00
2.4e+00
—
—
—
—
cases:16.90%
controls:11.13%
cases:16.90%
controls:5.35%
cases:11.27%
controls:1.13%
—
—
—
—
—
—
—
—
12
79
59
631
12
38
59
672
8
8
63
702
—
—
—
—
Erythrocyte [DistWidth] in Red Blood Cells
30385-9 [3002385]
3.0e-01
6.5e-01
1.5e+00
—
2.2e+00
—
—
cases:39.44%
controls:32.54%
cases:35.21%
controls:22.11%
cases:22.54%
controls:6.06%
—
—
cases:26.67%
controls:3.96%
—
—
—
—
28
231
43
479
25
157
46
553
16
43
55
667
—
16
28
44
679
—
—
MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 [3003338]
-1.2e-01
4.2e-01
1.6e+00
—
2.0e+00
—
—
cases:33.80%
controls:36.62%
cases:33.80%
controls:25.21%
cases:22.54%
controls:5.49%
—
—
cases:20.00%
controls:3.25%
—
—
—
—
24
260
47
450
24
179
47
531
16
39
55
671
—
12
23
48
684
—
—
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 [40764999]
9.0e-02
4.2e-01
1.7e+00
1.0e+50
1.9e+00
—
—
cases:29.58%
controls:27.75%
cases:29.58%
controls:21.69%
cases:21.13%
controls:4.79%
cases:18.31%
controls:0.00%
cases:21.67%
controls:3.96%
—
—
—
—
21
197
50
513
21
154
50
556
15
34
56
676
13
0
58
710
13
28
47
679
—
—
MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]
4.0e-02
3.3e-01
1.5e+00
—
2.1e+00
—
—
cases:47.89%
controls:46.90%
cases:42.25%
controls:34.51%
cases:29.58%
controls:8.73%
—
—
cases:31.67%
controls:5.52%
—
—
—
—
34
333
37
377
30
245
41
465
21
62
50
648
—
19
39
41
668
—
—
MCH [Entitic mass]
28539-5 [3035941]
4.5e-02
3.3e-01
1.5e+00
—
2.1e+00
—
—
cases:47.89%
controls:46.76%
cases:42.25%
controls:34.51%
cases:29.58%
controls:8.73%
—
—
cases:31.67%
controls:5.52%
—
—
—
—
34
332
37
378
30
245
41
465
21
62
50
648
—
19
39
41
668
—
—
Hemoglobin [Mass/volume] in Blood
718-7 [3000963]
3.4e-02
3.2e-01
1.5e+00
—
2.1e+00
—
—
cases:47.89%
controls:47.04%
cases:42.25%
controls:34.79%
cases:29.58%
controls:8.73%
—
—
cases:31.67%
controls:5.52%
—
—
—
—
34
334
37
376
30
247
41
463
21
62
50
648
—
19
39
41
668
—
—
Platelets [#/volume] in Blood
26515-7 [3007461]
4.5e-02
3.2e-01
1.5e+00
—
2.1e+00
—
—
cases:47.89%
controls:46.76%
cases:42.25%
controls:34.65%
cases:29.58%
controls:8.73%
—
—
cases:31.67%
controls:5.52%
—
—
—
—
34
332
37
378
30
246
41
464
21
62
50
648
—
19
39
41
668
—
—
Leukocytes [#/volume] in Blood
26464-8 [3010813]
4.0e-02
3.2e-01
1.5e+00
—
2.1e+00
—
—
cases:47.89%
controls:46.90%
cases:42.25%
controls:34.65%
cases:29.58%
controls:8.73%
—
—
cases:31.67%
controls:5.52%
—
—
—
—
34
333
37
377
30
246
41
464
21
62
50
648
—
19
39
41
668
—
—
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]
4.0e-02
3.2e-01
1.5e+00
—
2.1e+00
—
—
cases:47.89%
controls:46.90%
cases:42.25%
controls:34.65%
cases:29.58%
controls:8.73%
—
—
cases:31.67%
controls:5.52%
—
—
—
—
34
333
37
377
30
246
41
464
21
62
50
648
—
19
39
41
668
—
—
Erythrocytes [#/volume] in Blood
26453-1 [3026361]
4.0e-02
3.2e-01
1.5e+00
—
2.1e+00
—
—
cases:47.89%
controls:46.90%
cases:42.25%
controls:34.65%
cases:29.58%
controls:8.73%
—
—
cases:31.67%
controls:5.52%
—
—
—
—
34
333
37
377
30
246
41
464
21
62
50
648
—
19
39
41
668
—
—
Urinalysis macro (dipstick) panel - Urine
24357-6 [3037467]
1.3e-01
1.1e+00
2.4e+00
—
—
—
—
cases:22.54%
controls:20.28%
cases:22.54%
controls:8.45%
cases:8.45%
controls:0.85%
—
—
—
—
—
—
—
—
16
144
55
566
16
60
55
650
6
6
65
704
—
—
—
—
Upper gastrointestinal surgery
106 [44777669]
1.1e+00
2.1e+00
—
—
—
—
—
cases:22.54%
controls:8.45%
cases:18.31%
controls:2.54%
—
—
—
—
—
—
—
—
—
—
16
60
55
650
13
18
58
692
—
—
—
—
—
calcium (different salts in combination); oral
A12AA20 [21600872]
6.3e-01
1.2e+00
—
—
2.0e+00
—
—
cases:18.31%
controls:10.70%
cases:21.13%
controls:7.46%
—
—
—
—
cases:15.00%
controls:2.40%
—
—
—
—
13
76
58
634
15
53
56
657
—
—
9
17
51
690
—
—
Case Management Agency
251B00000X [38004193]
1.5e-01
7.3e-02
5.5e-01
3.2e+00
5.1e-01
—
—
cases:71.83%
controls:68.73%
cases:64.79%
controls:63.10%
cases:40.85%
controls:28.45%
cases:32.39%
controls:1.97%
cases:36.67%
controls:25.88%
—
—
—
—
51
488
20
222
46
448
25
262
29
202
42
508
23
14
48
696
22
183
38
524
—
—
Holo-transcobalamin II [Moles/volume] in Serum
72160-5 [43054903]
4.0e-01
1.2e+00
—
—
2.9e+00
—
—
cases:15.49%
controls:10.99%
cases:15.49%
controls:5.35%
—
—
—
—
cases:11.67%
controls:0.71%
—
—
—
—
11
78
60
632
11
38
60
672
—
—
7
5
53
702
—
—
Outpatient Visit
OP [9202]
6.0e-01
7.9e-01
1.4e+00
—
1.5e+00
—
—
cases:87.32%
controls:79.01%
cases:73.24%
controls:55.35%
cases:29.58%
controls:9.44%
—
—
cases:31.67%
controls:9.34%
—
—
—
—
62
561
9
149
52
393
19
317
21
67
50
643
—
19
66
41
641
—
—
Epithelial cells.squamous [#/volume] in Urine by Automated count
51486-9 [3029879]
—
2.9e+00
—
—
—
—
—
—
—
cases:11.27%
controls:0.70%
—
—
—
—
—
—
—
—
—
—
—
8
5
63
705
—
—
—
—
—
Laboratory Visit
OMOP4822461 [32036]
-1.1e-02
3.2e-01
1.3e+00
—
1.5e+00
—
—
cases:50.70%
controls:50.99%
cases:49.30%
controls:41.41%
cases:35.21%
controls:13.10%
—
—
cases:35.00%
controls:11.17%
—
—
—
—
36
362
35
348
35
294
36
416
25
93
46
617
—
21
79
39
628
—
—
Epithelial cells.non-squamous [#/volume] in Urine by Automated count
51485-1 [3030306]
4.4e-01
2.7e+00
—
—
—
—
—
cases:7.04%
controls:4.65%
cases:12.68%
controls:0.99%
—
—
—
—
—
—
—
—
—
—
5
33
66
677
9
7
62
703
—
—
—
—
—
Outpatient Hospital
22 [8756]
1.0e+00
1.7e+00
—
1.0e+50
—
—
—
cases:45.07%
controls:23.10%
cases:28.17%
controls:6.90%
—
—
cases:11.27%
controls:0.00%
—
—
—
—
—
—
32
164
39
546
20
49
51
661
—
8
0
63
710
—
—
—
Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma
2324-2 [3026910]
5.0e-01
8.4e-01
2.6e+00
—
—
—
—
cases:25.35%
controls:17.04%
cases:11.27%
controls:5.21%
cases:8.45%
controls:0.70%
—
—
—
—
—
—
—
—
18
121
53
589
8
37
63
673
6
5
65
705
—
—
—
—
Respiratory syncytial virus RNA [Identifier] in Specimen by NAA with probe detection
40987-0 [3043924]
—
2.6e+00
—
—
—
—
—
—
—
cases:8.45%
controls:0.70%
—
—
—
—
—
—
—
—
—
—
—
6
5
65
705
—
—
—
—
—
Influenza virus B RNA [Presence] in Specimen by NAA with probe detection
40982-1 [3038288]
—
2.6e+00
—
—
—
—
—
—
—
cases:8.45%
controls:0.70%
—
—
—
—
—
—
—
—
—
—
—
6
5
65
705
—
—
—
—
—
Child and Adolescent Psychiatry
OMOP4821986 [45756756]
8.1e-01
1.1e+00
—
—
2.5e+00
—
—
cases:8.45%
controls:3.94%
cases:7.04%
controls:2.39%
—
—
—
—
cases:8.33%
controls:0.71%
—
—
—
—
6
28
65
682
5
17
66
693
—
—
5
5
55
702
—
—
Pediatric Medicine
37 [38004477]
6.3e-01
7.2e-01
—
1.0e+50
2.4e+00
—
—
cases:18.31%
controls:10.70%
cases:9.86%
controls:5.07%
—
—
cases:9.86%
controls:0.00%
cases:11.67%
controls:1.13%
—
—
—
—
13
76
58
634
7
36
64
674
—
7
0
64
710
7
8
53
699
—
—
Influenza virus A RNA [Presence] in Specimen by NAA with probe detection
34487-9 [3044938]
—
2.4e+00
—
—
—
—
—
—
—
cases:8.45%
controls:0.85%
—
—
—
—
—
—
—
—
—
—
—
6
6
65
704
—
—
—
—
—
Thyroxine (T4) free [Moles/volume] in Serum or Plasma
14920-3 [3008486]
3.7e-01
3.1e-01
1.7e+00
—
2.4e+00
—
—
cases:30.99%
controls:23.66%
cases:15.49%
controls:11.83%
cases:8.45%
controls:1.69%
—
—
cases:13.33%
controls:1.41%
—
—
—
—
22
168
49
542
11
84
60
626
6
12
65
698
—
8
10
52
697
—
—
citalopram; oral, parenteral
N06AB04 [21604712]
—
2.4e+00
—
—
—
—
—
—
—
cases:7.04%
controls:0.70%
—
—
—
—
—
—
—
—
—
—
—
5
5
66
705
—
—
—
—
—
Bacteria [Presence] in Urine
87829-8 [36304419]
7.4e-01
2.4e+00
—
—
—
—
—
cases:15.49%
controls:8.03%
cases:19.72%
controls:2.25%
—
—
—
—
—
—
—
—
—
—
11
57
60
653
14
16
57
694
—
—
—
—
—
12 lead EKG panel
34534-8 [3044889]
2.9e-01
8.9e-01
—
—
2.4e+00
—
—
cases:23.94%
controls:19.01%
cases:19.72%
controls:9.15%
—
—
—
—
cases:8.33%
controls:0.85%
—
—
—
—
17
135
54
575
14
65
57
645
—
—
5
6
55
701
—
—
Magnesium [Moles/volume] in Serum or Plasma
2601-3 [3012095]
1.2e+00
2.3e+00
—
—
1.0e+50
—
—
cases:11.27%
controls:3.52%
cases:12.68%
controls:1.41%
—
—
—
—
cases:18.33%
controls:0.00%
—
—
—
—
8
25
63
685
9
10
62
700
—
—
11
0
49
707
—
—
Urinalysis microscopic panel [#/volume] - Urine by Automated count
50554-5 [3029287]
6.4e-01
2.3e+00
—
—
—
—
—
cases:16.90%
controls:9.72%
cases:22.54%
controls:2.82%
—
—
—
—
—
—
—
—
—
—
12
69
59
641
16
20
55
690
—
—
—
—
—
Gas panel - Venous blood
24339-4 [3000991]
—
2.3e+00
—
—
—
—
—
—
—
cases:9.86%
controls:1.13%
—
—
—
—
—
—
—
—
—
—
—
7
8
64
702
—
—
—
—
—
Casts [#/volume] in Urine by Automated count
51483-6 [3030467]
8.0e-01
2.2e+00
—
—
—
—
—
cases:15.49%
controls:7.61%
cases:18.31%
controls:2.39%
—
—
—
—
—
—
—
—
—
—
11
54
60
656
13
17
58
693
—
—
—
—
—
Phosphate [Moles/volume] in Serum or Plasma
14879-1 [3003458]
1.1e+00
2.2e+00
—
—
—
—
—
cases:11.27%
controls:3.94%
cases:15.49%
controls:1.97%
—
—
—
—
—
—
—
—
—
—
8
28
63
682
11
14
60
696
—
—
—
—
—
Other and unspecified abdominal pain
R10.4 [45568113]
8.1e-01
2.2e+00
—
—
—
—
—
cases:12.68%
controls:6.06%
cases:11.27%
controls:1.41%
—
—
—
—
—
—
—
—
—
—
9
43
62
667
8
10
63
700
—
—
—
—
—
Troponin T.cardiac [Mass/volume] in Serum or Plasma
6598-7 [3019800]
2.4e-01
2.2e+00
—
—
—
—
—
cases:9.86%
controls:7.89%
cases:14.08%
controls:1.83%
—
—
—
—
—
—
—
—
—
—
7
56
64
654
10
13
61
697
—
—
—
—
—
CBC panel - Blood by Automated count
58410-2 [40761511]
1.2e-01
7.4e-01
1.3e+00
—
2.1e+00
—
—
cases:40.85%
controls:38.03%
cases:35.21%
controls:20.56%
cases:14.08%
controls:4.08%
—
—
cases:20.00%
controls:2.83%
—
—
—
—
29
270
42
440
25
146
46
564
10
29
61
681
—
12
20
48
687
—
—
Limited function/disability NOS
A28 [2002000162]
1.2e+00
2.1e+00
—
—
—
—
—
cases:7.04%
controls:2.25%
cases:9.86%
controls:1.27%
—
—
—
—
—
—
—
—
—
—
5
16
66
694
7
9
64
701
—
—
—
—
—
Bacteria identified in Blood by Culture
600-7 [3023368]
4.4e-01
2.1e+00
—
—
—
—
—
cases:8.45%
controls:5.63%
cases:9.86%
controls:1.27%
—
—
—
—
—
—
—
—
—
—
6
40
65
670
7
9
64
701
—
—
—
—
—
Erythrocytes [#/volume] in Urine
30391-7 [3002582]
6.7e-01
2.1e+00
—
—
—
—
—
cases:15.49%
controls:8.59%
cases:21.13%
controls:3.10%
—
—
—
—
—
—
—
—
—
—
11
61
60
649
15
22
56
688
—
—
—
—
—
oxycodone; oral, parenteral
N02AA05 [21604260]
—
2.1e+00
—
—
—
—
—
—
—
cases:8.45%
controls:1.13%
—
—
—
—
—
—
—
—
—
—
—
6
8
65
702
—
—
—
—
—
Paediatric neurology
421 [44777781]
—
2.1e+00
—
—
—
—
—
—
—
cases:8.45%
controls:1.13%
—
—
—
—
—
—
—
—
—
—
—
6
8
65
702
—
—
—
—
—
quetiapine; oral
N05AH04 [21604544]
8.2e-01
2.0e+00
—
—
—
—
—
cases:7.04%
controls:3.24%
cases:12.68%
controls:1.83%
—
—
—
—
—
—
—
—
—
—
5
23
66
687
9
13
62
697
—
—
—
—
—
pH of Serum or Plasma
2753-2 [3018418]
7.9e-01
2.0e+00
—
—
—
—
—
cases:14.08%
controls:6.90%
cases:18.31%
controls:2.82%
—
—
—
—
—
—
—
—
—
—
10
49
61
661
13
20
58
690
—
—
—
—
—
Osmolality of Urine
2695-5 [3026782]
7.4e-01
2.0e+00
—
—
—
—
—
cases:8.45%
controls:4.23%
cases:9.86%
controls:1.41%
—
—
—
—
—
—
—
—
—
—
6
30
65
680
7
10
64
700
—
—
—
—
—
Erythrocyte sedimentation rate [Velocity] in Red Blood Cells by Westergren method
4537-7 [3013707]
2.6e-01
4.9e-01
2.0e+00
—
—
—
—
cases:25.35%
controls:20.70%
cases:15.49%
controls:10.14%
cases:9.86%
controls:1.41%
—
—
—
—
—
—
—
—
18
147
53
563
11
72
60
638
7
10
64
700
—
—
—
—
Thyrotropin [Units/volume] in Serum or Plasma
3016-3 [3009201]
1.0e-01
9.7e-02
1.8e+00
—
2.0e+00
—
—
cases:33.80%
controls:31.55%
cases:18.31%
controls:16.90%
cases:9.86%
controls:1.83%
—
—
cases:15.00%
controls:2.26%
—
—
—
—
24
224
47
486
13
120
58
590
7
13
64
697
—
9
16
51
691
—
—
Folate [Moles/volume] in Serum or Plasma
14732-2 [3021960]
7.0e-01
2.0e+00
—
—
—
—
—
cases:8.45%
controls:4.37%
cases:14.08%
controls:2.11%
—
—
—
—
—
—
—
—
—
—
6
31
65
679
10
15
61
695
—
—
—
—
—
Emergency Room and Inpatient Visit
ERIP [262]
6.7e-01
2.0e+00
1.0e+50
1.0e+50
—
—
—
cases:12.68%
controls:6.90%
cases:18.31%
controls:2.96%
cases:7.04%
controls:0.00%
cases:16.90%
controls:0.00%
—
—
—
—
—
—
9
49
62
661
13
21
58
689
5
0
66
710
12
0
59
710
—
—
—
diazepam; oral, parenteral, rectal
N05BA01 [21604566]
1.1e+00
1.9e+00
—
—
—
—
—
cases:7.04%
controls:2.54%
cases:9.86%
controls:1.55%
—
—
—
—
—
—
—
—
—
—
5
18
66
692
7
11
64
699
—
—
—
—
—
metoclopramide; oral, parenteral, rectal
A03FA01 [21600484]
1.9e+00
—
—
—
—
—
—
cases:16.90%
controls:2.96%
—
—
—
—
—
—
—
—
—
—
—
—
12
21
59
689
—
—
—
—
—
—
Leukocytes [#/volume] in Urine
30405-5 [3018095]
5.7e-01
1.8e+00
—
—
—
—
—
cases:15.49%
controls:9.44%
cases:21.13%
controls:4.08%
—
—
—
—
—
—
—
—
—
—
11
67
60
643
15
29
56
681
—
—
—
—
—
Gastroenterology
10 [38004455]
1.7e+00
1.6e+00
—
—
—
—
—
cases:21.13%
controls:4.51%
cases:9.86%
controls:2.11%
—
—
—
—
—
—
—
—
—
—
15
32
56
678
7
15
64
695
—
—
—
—
—
oxazepam; oral
N05BA04 [21604569]
1.0e+00
1.7e+00
—
—
—
—
—
cases:9.86%
controls:3.80%
cases:11.27%
controls:2.25%
—
—
—
—
—
—
—
—
—
—
7
27
64
683
8
16
63
694
—
—
—
—
—
Albumin [Presence] in Urine by Test strip
50949-7 [3029937]
6.3e-01
1.7e+00
—
—
—
—
—
cases:11.27%
controls:6.34%
cases:11.27%
controls:2.25%
—
—
—
—
—
—
—
—
—
—
8
45
63
665
8
16
63
694
—
—
—
—
—
Cathetrisation of vein
TPH04 [2001309597]
1.6e+00
—
—
—
—
—
—
cases:12.68%
controls:2.82%
—
—
—
—
—
—
—
—
—
—
—
—
9
20
62
690
—
—
—
—
—
—
Inpatient Visit
IP [9201]
5.5e-01
1.6e+00
—
1.0e+50
—
—
—
cases:15.49%
controls:9.58%
cases:14.08%
controls:3.24%
—
—
cases:7.04%
controls:0.00%
—
—
—
—
—
—
11
68
60
642
10
23
61
687
—
5
0
66
710
—
—
—
General Practice
1 [38004446]
8.2e-01
1.6e+00
—
1.0e+50
—
—
—
cases:28.17%
controls:14.79%
cases:25.35%
controls:6.62%
—
—
cases:12.68%
controls:0.00%
—
—
—
—
—
—
20
105
51
605
18
47
53
663
—
9
0
62
710
—
—
—
Emergency Medicine
93 [38004510]
8.9e-03
1.5e+00
—
1.0e+50
1.7e+00
—
—
cases:19.72%
controls:19.58%
cases:25.35%
controls:6.90%
—
—
cases:18.31%
controls:0.00%
cases:8.33%
controls:1.56%
—
—
—
—
14
139
57
571
18
49
53
661
—
13
0
58
710
5
11
55
696
—
—
Prealbumin [Mass/volume] in Serum or Plasma
14338-8 [3013742]
1.5e+00
1.7e+00
—
—
—
—
—
cases:14.08%
controls:3.52%
cases:8.45%
controls:1.69%
—
—
—
—
—
—
—
—
—
—
10
25
61
685
6
12
65
698
—
—
—
—
—
pantoprazole; oral, parenteral
A02BC02 [21600097]
6.4e-01
1.2e+00
—
—
1.2e+00
—
—
cases:25.35%
controls:15.21%
cases:26.76%
controls:9.72%
—
—
—
—
cases:8.33%
controls:2.55%
—
—
—
—
18
108
53
602
19
69
52
641
—
—
5
18
55
689
—
—
naproxen; oral, rectal
M01AE02 [21603968]
1.2e+00
1.5e+00
—
—
—
—
—
cases:19.72%
controls:7.18%
cases:7.04%
controls:1.69%
—
—
—
—
—
—
—
—
—
—
14
51
57
659
5
12
66
698
—
—
—
—
—
naproxcinod
M01AE18 [40254094]
1.2e+00
1.5e+00
—
—
—
—
—
cases:19.72%
controls:7.18%
cases:7.04%
controls:1.69%
—
—
—
—
—
—
—
—
—
—
14
51
57
659
5
12
66
698
—
—
—
—
—
Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1920-8 [3013721]
1.1e+00
—
—
—
—
—
—
cases:21.13%
controls:8.31%
—
—
—
—
—
—
—
—
—
—
—
—
15
59
56
651
—
—
—
—
—
—
Fall on same level involving ice and snow
W00 [45756242]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.69%
—
—
—
—
—
—
—
—
—
—
—
—
0
12
71
698
—
—
—
—
—
—
Aortic (valve) stenosis
I35.0 [45576869]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.27%
cases:0.00%
controls:0.85%
—
—
—
—
—
—
—
—
—
—
0
9
71
701
0
6
71
704
—
—
—
—
—
Rectal ultrasound examination of prostate
KE1BE [2001306106]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.27%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
71
701
—
—
—
—
—
—
Home Visit
OMOP4822459 [581476]
9.8e-01
9.3e-01
—
—
—
—
—
cases:14.08%
controls:5.77%
cases:8.45%
controls:3.52%
—
—
—
—
—
—
—
—
—
—
10
41
61
669
6
25
65
685
—
—
—
—
—
apixaban; oral
B01AF02 [43534762]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.27%
cases:0.00%
controls:1.55%
—
—
—
—
—
—
—
—
—
—
0
9
71
701
0
11
71
699
—
—
—
—
—
Two-surface restoration
SFA20 [2001310359]
-1.7e-01
—
—
—
—
—
—
cases:12.68%
controls:14.65%
—
—
—
—
—
—
—
—
—
—
—
—
9
104
62
606
—
—
—
—
—
—
Issue of medical certificate
Z02.7 [45537613]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.85%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
71
704
—
—
—
—
—
—
Ear microscopy
UDC00 [2001301558]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.13%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
71
702
—
—
—
—
—
—
Skin injury other
S19 [2002000984]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.70%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
71
705
—
—
—
—
—
—
Emergency use of U07.1 | COVID-19, virus identified
U07.1 [45756093]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.55%
—
—
—
—
—
—
—
—
—
—
—
—
0
11
71
699
—
—
—
—
—
—
Excessive and frequent menstruation with irregular cycle
N92.1 [45539073]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.70%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
71
705
—
—
—
—
—
—
Polysomnography panel
90568-7 [1002224]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.70%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
71
705
—
—
—
—
—
—
Phakoemulsification with implantation of artificial lens in posterior chamber
CJE20 [2001301342]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.55%
—
—
—
—
—
—
—
—
—
—
—
0
11
71
699
—
—
—
—
—
Helicobacter pylori Ab [Units/volume] in Serum
7900-4 [3017895]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.70%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
71
705
—
—
—
—
—
—
Skin colour change
S08 [2002000973]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.70%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
71
705
—
—
—
—
—
—
chloramphenicol; ointment
D06AX02 [21602063]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.70%
cases:0.00%
controls:0.85%
—
—
—
—
—
—
—
—
—
—
0
5
71
705
0
6
71
704
—
—
—
—
—
Ear pain/earache
H01 [2002000475]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.85%
—
—
—
—
—
—
—
—
—
—
—
0
6
71
704
—
—
—
—
—
Sleep apnoea
G47.3 [45562094]
—
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.13%
—
—
—
—
—
—
—
—
—
—
0
8
71
702
—
—
—
—
chondroitin sulfate
M01AX25 [21604013]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:2.39%
—
—
—
—
—
—
—
—
—
—
—
—
0
17
71
693
—
—
—
—
—
—
Spirometry
127783003 [4133840]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.41%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
71
700
—
—
—
—
—
—
Follow-up examination after surgery for other conditions
Z09.0 [45576131]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.85%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
71
704
—
—
—
—
—
—
fusidic acid
S01AA13 [21603564]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.27%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
71
701
—
—
—
—
—
—
Assessment of need for rehabilitation and/or rehabilitation plan
SPAT1220 [2001700321]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.70%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
71
705
—
—
—
—
—
—
Type 2 diabetes mellitus, with multiple complications
E11.7 [45561950]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.70%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
71
705
—
—
—
—
—
—
Contusion of finger(s) without damage to nail
S60.0 [45535417]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.85%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
71
704
—
—
—
—
—
—
Guidance concerning treatment of rash and skin
SPAT1156 [2001700257]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.27%
—
—
—
—
—
—
—
—
—
—
—
0
9
71
701
—
—
—
—
—
Extraction of tooth
EBA00 [2001301923]
8.2e-02
—
—
—
—
—
—
cases:9.86%
controls:9.15%
—
—
—
—
—
—
—
—
—
—
—
—
7
65
64
645
—
—
—
—
—
—
ipratropium bromide; inhalant
R03BB01 [21603293]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.85%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
71
704
—
—
—
—
—
—
Adenocarcinoma, NOS, of prostate gland
8140/3-C61.9 [44499685]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.13%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
71
702
—
—
—
—
—
—
Hypodontia
K00.00 [2000502614]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.41%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
71
700
—
—
—
—
—
—
Migraine with aura [classical migraine]
G43.1 [45562086]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.13%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
71
702
—
—
—
—
—
—
combinations of penicillins
J01CR50 [21602867]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.70%
—
—
—
—
—
—
—
—
—
—
—
0
5
71
705
—
—
—
—
—
Metatarsalgia
M77.4 [45601544]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.85%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
71
704
—
—
—
—
—
—
Skin symptom/complaint other
S29 [2002000993]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.27%
—
—
—
—
—
—
—
—
—
—
—
0
9
71
701
—
—
—
—
—
levothyroxine sodium; oral, parenteral
H03AA01 [21602754]
—
-2.0e-01
—
—
—
—
—
—
—
cases:7.04%
controls:8.45%
—
—
—
—
—
—
—
—
—
—
—
5
60
66
650
—
—
—
—
—
Wrist symptom/complaint
L11 [2002000635]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.27%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
71
701
—
—
—
—
—
—
Hepatitis C virus Ab [Presence] in Serum
16128-1 [3017143]
9.6e-01
—
—
—
—
—
—
cases:7.04%
controls:2.82%
—
—
—
—
—
—
—
—
—
—
—
—
5
20
66
690
—
—
—
—
—
—
Epithelial cells [#/volume] in Urine
30383-4 [3000850]
1.0e+00
1.6e+00
—
—
—
—
—
cases:11.27%
controls:4.37%
cases:9.86%
controls:2.25%
—
—
—
—
—
—
—
—
—
—
8
31
63
679
7
16
64
694
—
—
—
—
—
prednisolone; oral, parenteral
H02AB06 [21602734]
3.9e-01
8.9e-01
—
—
—
—
—
cases:11.27%
controls:7.89%
cases:8.45%
controls:3.66%
—
—
—
—
—
—
—
—
—
—
8
56
63
654
6
26
65
684
—
—
—
—
—
potassium chloride; oral
A12BA01 [21600877]
—
1.7e+00
—
—
—
—
—
—
—
cases:7.04%
controls:1.41%
—
—
—
—
—
—
—
—
—
—
—
5
10
66
700
—
—
—
—
—
Psychosocial counselling and guidance
SPAT1307 [2001700408]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.85%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
71
704
—
—
—
—
—
—
losartan; oral
C09CA01 [21601824]
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.70%
—
—
—
—
—
—
—
—
0
12
60
695
—
—
dexamethasone and antiinfectives
S03CA01 [21605206]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.41%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
71
700
—
—
—
—
—
—
Hyaline casts [#/volume] in Urine by Automated count
51484-4 [3030981]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.85%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
71
704
—
—
—
—
—
—
Carbon dioxide [Partial pressure] in Arterial blood
2019-8 [3027946]
1.3e+00
—
—
—
—
—
—
cases:7.04%
controls:1.97%
—
—
—
—
—
—
—
—
—
—
—
—
5
14
66
696
—
—
—
—
—
—
letrozole; oral
L02BG04 [21603842]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.69%
cases:0.00%
controls:0.70%
—
—
—
—
—
—
—
—
—
—
0
12
71
698
0
5
71
705
—
—
—
—
—
Shoulder X-ray examination without contrast
NB1AA [2001307225]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.41%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
71
700
—
—
—
—
—
—
Pediatric Surgery
OMOP4822020 [45756819]
7.2e-01
—
—
—
—
—
—
cases:9.86%
controls:5.07%
—
—
—
—
—
—
—
—
—
—
—
—
7
36
64
674
—
—
—
—
—
—
insulin aspart; parenteral
A10AB05 [21600719]
-1.0e+50
—
-1.0e+50
—
—
—
—
cases:0.00%
controls:3.24%
—
—
cases:0.00%
controls:1.41%
—
—
—
—
—
—
—
—
0
23
71
687
—
0
10
71
700
—
—
—
—
Gastro-oesophageal reflux disease without oesophagitis
K21.9 [45538509]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.85%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
71
704
—
—
—
—
—
—
Thrombin time
3243-3 [3036489]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.69%
—
—
—
—
—
—
—
—
—
—
—
—
0
12
71
698
—
—
—
—
—
—
omeprazole; oral, parenteral
A02BC01 [21600096]
1.6e+00
—
—
—
—
—
—
cases:9.86%
controls:2.25%
—
—
—
—
—
—
—
—
—
—
—
—
7
16
64
694
—
—
—
—
—
—
Back syndrome with radiating pain
L86 [2002000705]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.70%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
71
705
—
—
—
—
—
—
Periapical abscess without sinus
K04.7 [45586692]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.27%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
71
701
—
—
—
—
—
—
Other and unspecified ventral hernia without obstruction or gangrene
K43.9 [45533594]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.85%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
71
704
—
—
—
—
—
—
Zoster without complication
B02.9 [45581143]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.27%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
71
701
—
—
—
—
—
—
Extraction of root of tooth
EBA30 [2001301929]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.99%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
71
703
—
—
—
—
—
—
Pharmacy visit
OMOP4822462 [581458]
-3.7e-01
3.7e-01
6.4e-01
—
6.2e-01
—
—
cases:90.14%
controls:92.96%
cases:87.32%
controls:82.68%
cases:63.38%
controls:47.75%
—
—
cases:58.33%
controls:43.00%
—
—
—
—
64
660
7
50
62
587
9
123
45
339
26
371
—
35
304
25
403
—
—
Sexual health counselling
SPAT1308 [2001700409]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.13%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
71
702
—
—
—
—
—
—
Tissue transglutaminase IgA Ab [Units/volume] in Serum
31017-7 [3019050]
5.8e-01
8.2e-01
—
—
1.0e+50
—
—
cases:9.86%
controls:5.77%
cases:7.04%
controls:3.24%
—
—
—
—
cases:13.33%
controls:0.00%
—
—
—
—
7
41
64
669
5
23
66
687
—
—
8
0
52
707
—
—
Routine child health examination
Z00.1 [45561606]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.55%
—
—
—
—
—
—
—
—
—
—
—
0
11
71
699
—
—
—
—
—
chloramphenicol
G01AA05 [21602367]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.70%
cases:0.00%
controls:0.85%
—
—
—
—
—
—
—
—
—
—
0
5
71
705
0
6
71
704
—
—
—
—
—
mupirocin; nasal
R01AX06 [21603201]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.70%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
71
705
—
—
—
—
—
—
metoprolol; oral, parenteral
C07AB02 [21601684]
—
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.83%
—
—
—
—
—
—
—
—
—
—
0
13
71
697
—
—
—
—
Insertion of (intrauterine) contraceptive device
Z30.1 [45537626]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.27%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
71
701
—
—
—
—
—
—
Urate [Moles/volume] in Serum or Plasma
14933-6 [3026493]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:5.49%
—
—
—
—
—
—
—
—
—
—
—
—
0
39
71
671
—
—
—
—
—
—
Hemoglobin [Presence] in Urine by Test strip
5794-3 [3011397]
5.5e-01
1.6e+00
—
—
—
—
—
cases:8.45%
controls:5.07%
cases:9.86%
controls:2.25%
—
—
—
—
—
—
—
—
—
—
6
36
65
674
7
16
64
694
—
—
—
—
—
Campylobacter sp identified in Tissue by Organism specific culture
20740-7 [3006418]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.70%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
71
705
—
—
—
—
—
—
clindamycin
D10AF01 [21602305]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.13%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
71
702
—
—
—
—
—
—
candesartan; oral
C09CA06 [21601829]
—
-1.0e+50
-1.0e+50
—
-1.0e+50
—
—
—
—
cases:0.00%
controls:4.37%
cases:0.00%
controls:1.83%
—
—
cases:0.00%
controls:0.99%
—
—
—
—
—
0
31
71
679
0
13
71
697
—
0
7
60
700
—
—
Essential (primary) hypertension
I10 [45591453]
-3.8e-01
-3.2e-01
1.1e+00
—
—
—
—
cases:14.08%
controls:19.30%
cases:7.04%
controls:9.44%
cases:7.04%
controls:2.39%
—
—
—
—
—
—
—
—
10
137
61
573
5
67
66
643
5
17
66
693
—
—
—
—
Coronary angiography
AN1 [2000200163]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.85%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
71
704
—
—
—
—
—
—
aPTT in Platelet poor plasma by Coagulation assay
14979-9 [3018677]
4.4e-01
—
—
—
—
—
—
cases:7.04%
controls:4.65%
—
—
—
—
—
—
—
—
—
—
—
—
5
33
66
677
—
—
—
—
—
—
Tissue Pathology biopsy report
66121-5 [40768804]
-3.6e-02
—
—
—
—
—
—
cases:8.45%
controls:8.73%
—
—
—
—
—
—
—
—
—
—
—
—
6
62
65
648
—
—
—
—
—
—
Oral and dental health check by dental hygienist or dental assistant
SAB02 [2001310280]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:2.96%
cases:0.00%
controls:1.13%
—
—
—
—
—
—
—
—
—
—
0
21
71
689
0
8
71
702
—
—
—
—
—
Three-surface restoration
SFA30 [2001310360]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:2.39%
—
—
—
—
—
—
—
—
—
—
—
0
17
71
693
—
—
—
—
—
Dysthymia
F34.1 [45586238]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.70%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
71
705
—
—
—
—
—
—
brinzolamide, combinations
S01EC54 [45893490]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.99%
cases:0.00%
controls:0.85%
—
—
—
—
—
—
—
—
—
—
0
7
71
703
0
6
71
704
—
—
—
—
—
rivaroxaban; oral
B01AF01 [43534761]
-1.0e+50
-1.0e+50
-1.0e+50
—
—
—
—
cases:0.00%
controls:2.54%
cases:0.00%
controls:1.83%
cases:0.00%
controls:0.70%
—
—
—
—
—
—
—
—
0
18
71
692
0
13
71
697
0
5
71
705
—
—
—
—
acetylsalicylic acid; oral
B01AC06 [21600991]
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.85%
—
—
—
—
—
—
—
—
0
6
60
701
—
—
Naevus/mole
S82 [2002001046]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.85%
—
—
—
—
—
—
—
—
—
—
—
0
6
71
704
—
—
—
—
—
Spontaneous vertex delivery
O80.0 [45577661]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.13%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
71
702
—
—
—
—
—
—
Thyrotoxicosis with diffuse goitre
E05.0 [45600628]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.70%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
71
705
—
—
—
—
—
—
Treatment plan or consultation
WZC00 [2001310885]
1.5e-01
—
—
—
—
—
—
cases:9.86%
controls:8.59%
—
—
—
—
—
—
—
—
—
—
—
—
7
61
64
649
—
—
—
—
—
—
diclofenac; oral, parenteral, rectal
M01AB05 [21603945]
2.2e-01
—
—
—
—
—
—
cases:15.49%
controls:12.82%
—
—
—
—
—
—
—
—
—
—
—
—
11
91
60
619
—
—
—
—
—
—
loratadine; oral
R06AX13 [21603514]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.97%
—
—
—
—
—
—
—
—
—
—
—
—
0
14
71
696
—
—
—
—
—
—
Anorexia nervosa
F50.0 [45562053]
—
1.0e+50
—
—
—
—
—
—
—
cases:7.04%
controls:0.00%
—
—
—
—
—
—
—
—
—
—
—
5
0
66
710
—
—
—
—
—
salbutamol; inhalant
R03AC02 [21603256]
2.9e-02
1.5e-01
—
—
—
—
—
cases:18.31%
controls:17.89%
cases:9.86%
controls:8.59%
—
—
—
—
—
—
—
—
—
—
13
127
58
583
7
61
64
649
—
—
—
—
—
aciclovir
D06BB03 [21602085]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.99%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
71
703
—
—
—
—
—
—
Cephalometry with X-ray
EB1MA [2001301916]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.41%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
71
700
—
—
—
—
—
—
sildenafil; oral
G04BE03 [21602648]
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.97%
cases:0.00%
controls:0.85%
—
—
—
—
—
—
—
—
—
0
14
71
696
0
6
71
704
—
—
—
—
Medical observation and evaluation for suspected diseases and conditions, ruled out
Z03 [45552058]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.97%
cases:0.00%
controls:0.70%
—
—
—
—
—
—
—
—
—
—
0
14
71
696
0
5
71
705
—
—
—
—
—
salmeterol and fluticasone
R03AK06 [21603280]
—
-1.0e+50
-1.0e+50
—
-1.0e+50
—
—
—
—
cases:0.00%
controls:1.97%
cases:0.00%
controls:0.99%
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
0
14
71
696
0
7
71
703
—
0
5
60
702
—
—
Fear of other disease NOS
A27 [2002000161]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.70%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
71
705
—
—
—
—
—
—
Transient cerebral ischaemic attack, unspecified
G45.9 [45542892]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.70%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
71
705
—
—
—
—
—
—
ethylmorphine; oral
R05DA01 [21603397]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:3.10%
—
—
—
—
—
—
—
—
—
—
—
—
0
22
71
688
—
—
—
—
—
—
Initiation, adjustment, discontinuation or repetition of medication
SPAT1253 [2001700354]
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
—
0
5
60
702
—
—
Measurement of mechanical axis of lower leg with X-ray
NJ2MA [2001308419]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.85%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
71
704
—
—
—
—
—
—
Allergic rhinitis due to pollen
J30.10 [2000502594]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.99%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
71
703
—
—
—
—
—
—
levonorgestrel
G03AC03 [21602499]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:2.11%
—
—
—
—
—
—
—
—
—
—
—
—
0
15
71
695
—
—
—
—
—
—
Anomalies of dental arch relationship
K07.25 [2000502771]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.99%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
71
703
—
—
—
—
—
—
Carbon dioxide [Partial pressure] in Venous blood
2021-4 [3021447]
—
1.7e+00
—
—
—
—
—
—
—
cases:7.04%
controls:1.41%
—
—
—
—
—
—
—
—
—
—
—
5
10
66
700
—
—
—
—
—
tizanidine; oral
M03BX02 [21604116]
3.0e-01
—
—
—
—
—
—
cases:11.27%
controls:8.59%
—
—
—
—
—
—
—
—
—
—
—
—
8
61
63
649
—
—
—
—
—
—
Fracture of upper end of humerus
S42.2 [45544677]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.85%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
71
704
—
—
—
—
—
—
fluconazole; oral, parenteral
J02AC01 [21603080]
7.4e-01
—
—
—
—
—
—
cases:8.45%
controls:4.23%
—
—
—
—
—
—
—
—
—
—
—
—
6
30
65
680
—
—
—
—
—
—
Panorama tomography of teeth and jaws or similar X-ray examination
EB1HA [2001301913]
-3.6e-02
—
—
—
—
—
—
cases:8.45%
controls:8.73%
—
—
—
—
—
—
—
—
—
—
—
—
6
62
65
648
—
—
—
—
—
—
Rheumatoid factor [Units/volume] in Serum or Plasma
11572-5 [3021614]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.99%
—
—
—
—
—
—
—
—
—
—
—
0
7
71
703
—
—
—
—
—
Other specified chronic obstructive pulmonary disease
J44.8 [45586673]
2.2e+00
—
—
—
—
—
—
cases:7.04%
controls:0.85%
—
—
—
—
—
—
—
—
—
—
—
—
5
6
66
704
—
—
—
—
—
—
Medical doctor
Z2221 [2001311556]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.69%
—
—
—
—
—
—
—
—
—
—
—
0
12
71
698
—
—
—
—
—
Laceration/cut
S18 [2002000983]
6.9e-01
—
—
—
—
—
—
cases:16.90%
controls:9.30%
—
—
—
—
—
—
—
—
—
—
—
—
12
66
59
644
—
—
—
—
—
—
Base excess in Venous blood by calculation
1927-3 [3002032]
—
1.7e+00
—
—
—
—
—
—
—
cases:7.04%
controls:1.41%
—
—
—
—
—
—
—
—
—
—
—
5
10
66
700
—
—
—
—
—
hydrocortisone; local oral
A01AC03 [21600036]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.13%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
71
702
—
—
—
—
—
—
Other specified counselling
Z71.8 [45581061]
2.6e-01
—
—
—
—
—
—
cases:7.04%
controls:5.49%
—
—
—
—
—
—
—
—
—
—
—
—
5
39
66
671
—
—
—
—
—
—
Endocrinology
46 [38004485]
1.3e+00
1.9e+00
—
—
—
—
—
cases:11.27%
controls:3.24%
cases:7.04%
controls:1.13%
—
—
—
—
—
—
—
—
—
—
8
23
63
687
5
8
66
702
—
—
—
—
—
piroxicam; ointment
M02AA07 [21604043]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.13%
—
—
—
—
—
—
—
—
—
—
—
0
8
71
702
—
—
—
—
—
Differential panel - Synovial fluid
29582-4 [3021788]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.70%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
71
705
—
—
—
—
—
—
Hand and fingers X-ray examination
ND2AA [2001307607]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.70%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
71
705
—
—
—
—
—
—
Presence of intraocular lens
Z96.1 [45585885]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.13%
—
—
—
—
—
—
—
—
—
—
—
0
8
71
702
—
—
—
—
—
Acne
L70 [45562544]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.70%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
71
705
—
—
—
—
—
—
Clinical Cytogenetics and Genomics
OMOP4822000 [32411]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:2.11%
—
—
—
—
—
—
—
—
—
—
—
—
0
15
71
695
—
—
—
—
—
—
Dental calculus supragingival
K03.64 [2000502689]
2.4e-01
—
—
—
—
—
—
cases:7.04%
controls:5.63%
—
—
—
—
—
—
—
—
—
—
—
—
5
40
66
670
—
—
—
—
—
—
Paroxysmal atrial fibrillation
I48.0 [45581776]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.13%
cases:0.00%
controls:0.85%
—
—
—
—
—
—
—
—
—
—
0
8
71
702
0
6
71
704
—
—
—
—
—
Other primary coxarthrosis
M16.1 [45591741]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.13%
—
—
—
—
—
—
—
—
—
—
—
0
8
71
702
—
—
—
—
—
dexamethasone and antiinfectives
S02CA06 [21605178]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.70%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
71
705
—
—
—
—
—
—
Demanding ultrsound examination of uterus, parametrium and lower part of abdomen with speciel methods
LC2DE [2001306545]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.70%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
71
705
—
—
—
—
—
—
SMOKING - SMOKE2: no - SMOKE3: never - SMOKE5: Unspecified
SMOKING-2-3-0 [2002330113]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.70%
—
—
—
—
—
—
—
—
—
—
—
0
5
71
705
—
—
—
—
—
Colonoscopy
SPAT1131 [2001700232]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.85%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
71
704
—
—
—
—
—
—
Other health check-up
SPAT1370 [2001700471]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.85%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
71
704
—
—
—
—
—
—
Streptococcus sp identified in Isolate by Organism specific culture
43389-6 [3042975]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.70%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
71
705
—
—
—
—
—
—
Pure hypercholesterolaemia
E78.0 [45542771]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.41%
—
—
—
—
—
—
—
—
—
—
—
0
10
71
700
—
—
—
—
—
Cholesterol in HDL/Cholesterol.total [Molar ratio] in Serum or Plasma
70200-1 [42868674]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:2.11%
—
—
—
—
—
—
—
—
—
—
—
0
15
71
695
—
—
—
—
—
lercanidipine; oral
C08CA13 [21601759]
—
-1.0e+50
-1.0e+50
—
-1.0e+50
—
—
—
—
cases:0.00%
controls:2.82%
cases:0.00%
controls:1.13%
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
0
20
71
690
0
8
71
702
—
0
5
60
702
—
—
Pediatric Hematology-Oncology
OMOP4822028 [45756811]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.85%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
71
704
—
—
—
—
—
—
Specific gravity of Urine by Refractometry
5810-7 [3019150]
—
1.3e+00
—
—
—
—
—
—
—
cases:8.45%
controls:2.39%
—
—
—
—
—
—
—
—
—
—
—
6
17
65
693
—
—
—
—
—
pregabalin; oral
N02BF02 [955152]
7.3e-01
—
-1.0e+50
—
-1.0e+50
—
—
cases:7.04%
controls:3.52%
—
—
cases:0.00%
controls:0.85%
—
—
cases:0.00%
controls:0.71%
—
—
—
—
5
25
66
685
—
0
6
71
704
—
0
5
60
702
—
—
Mixed anxiety and depressive disorder
F41.2 [45566845]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.13%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
71
702
—
—
—
—
—
—
ECG with 12 standard connections
XF400 [2001303368]
7.4e-01
-1.0e+50
—
—
—
—
—
cases:8.45%
controls:4.23%
cases:0.00%
controls:1.55%
—
—
—
—
—
—
—
—
—
—
6
30
65
680
0
11
71
699
—
—
—
—
—
covid-19, RNA-based vaccine
J07BN01 [954934]
6.9e-02
4.6e-01
—
—
-1.0e+50
—
—
cases:21.13%
controls:20.00%
cases:18.31%
controls:12.39%
—
—
—
—
cases:0.00%
controls:1.41%
—
—
—
—
15
142
56
568
13
88
58
622
—
—
0
10
60
697
—
—
Transvaginal ultrasound examination of uterus, parametria and lower abdomen
LC2BE [2001306544]
9.1e-01
—
—
—
—
—
—
cases:7.04%
controls:2.96%
—
—
—
—
—
—
—
—
—
—
—
—
5
21
66
689
—
—
—
—
—
—
isosorbide dinitrate; local oral, oral, sublingual, transdermal
C01DA08 [21600321]
—
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.70%
—
—
—
—
—
—
—
—
—
—
0
5
71
705
—
—
—
—
Paediatric Clinical Immunology and Allergy
255 [44777768]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.99%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
71
703
—
—
—
—
—
—
atorvastatin; oral
C10AA05 [21601860]
—
-1.6e-01
-1.0e+50
—
—
—
—
—
—
cases:7.04%
controls:8.17%
cases:0.00%
controls:2.25%
—
—
—
—
—
—
—
—
—
5
58
66
652
0
16
71
694
—
—
—
—
SMOKING - SMOKE2: no - SMOKE3: former - SMOKE5: Unspecified
SMOKING-2-2-0 [2002330110]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:4.37%
—
—
—
—
—
—
—
—
—
—
—
—
0
31
71
679
—
—
—
—
—
—
insulin (beef); parenteral
A10AD02 [21600730]
—
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.99%
—
—
—
—
—
—
—
—
—
—
0
7
71
703
—
—
—
—
Type 2 diabetes mellitus, without complications
E11.9 [45561952]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:5.92%
cases:0.00%
controls:3.66%
—
—
—
—
—
—
—
—
—
—
0
42
71
668
0
26
71
684
—
—
—
—
—
Swelling
A08 [2002000149]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.70%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
71
705
—
—
—
—
—
—
Oxygen [Partial pressure] in Arterial blood
2703-7 [3027801]
1.3e+00
—
—
—
—
—
—
cases:7.04%
controls:1.97%
—
—
—
—
—
—
—
—
—
—
—
—
5
14
66
696
—
—
—
—
—
—
combinations of corticosteroids
D07XB30 [21602188]
7.2e-02
7.8e-01
-1.0e+50
—
—
—
—
cases:11.27%
controls:10.56%
cases:9.86%
controls:4.79%
cases:0.00%
controls:0.70%
—
—
—
—
—
—
—
—
8
75
63
635
7
34
64
676
0
5
71
705
—
—
—
—
Oncology Clinic/Center
261QX0200X [38004268]
1.1e+00
—
—
—
—
—
—
cases:14.08%
controls:5.21%
—
—
—
—
—
—
—
—
—
—
—
—
10
37
61
673
—
—
—
—
—
—
vilanterol and fluticasone furoate
R03AK10 [43534841]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.85%
—
—
—
—
—
—
—
—
—
—
—
0
6
71
704
—
—
—
—
—
Combined assessment of mammary gland (mammography and ultrasound)
HA1RA [2001303907]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.70%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
71
705
—
—
—
—
—
—
Moderate depressive episode without somatic syndrome
F32.10 [2000501980]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.70%
—
—
—
—
—
—
—
—
—
—
—
0
5
71
705
—
—
—
—
—
Melanocytic naevi
D22 [45595739]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.13%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
71
702
—
—
—
—
—
—
Photography of fundus of eye
XCK10 [2001301381]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.70%
—
—
—
—
—
—
—
—
—
—
—
0
5
71
705
—
—
—
—
—
Weakness/tiredness general
A04 [2002000145]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:2.39%
—
—
—
—
—
—
—
—
—
—
—
—
0
17
71
693
—
—
—
—
—
—
Cystatin C [Mass/volume] in Serum or Plasma
33863-2 [3030366]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.99%
—
—
—
—
—
—
—
—
—
—
—
0
7
71
703
—
—
—
—
—
Coagulation factor VIII activity actual/normal in Platelet poor plasma by Coagulation assay
3209-4 [3019250]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.41%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
71
700
—
—
—
—
—
—
Acute suppurative otitis media
H66.0 [45572040]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.13%
—
—
—
—
—
—
—
—
—
—
—
0
8
71
702
—
—
—
—
—
clindamycin; vaginal
G01AA10 [21602372]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:2.54%
—
—
—
—
—
—
—
—
—
—
—
—
0
18
71
692
—
—
—
—
—
—
dabigatran etexilate; oral
B01AE07 [21601026]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.27%
cases:0.00%
controls:0.99%
—
—
—
—
—
—
—
—
—
—
0
9
71
701
0
7
71
703
—
—
—
—
—
Mouth breathing
R06.5 [45573006]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.13%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
71
702
—
—
—
—
—
—
codeine; oral
R05DA04 [21603399]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:2.82%
—
—
—
—
—
—
—
—
—
—
—
—
0
20
71
690
—
—
—
—
—
—
econazole; vaginal
G01AF05 [21602395]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.70%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
71
705
—
—
—
—
—
—
dexamethasone
S02BA06 [21605168]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.70%
cases:0.00%
controls:0.99%
—
—
—
—
—
—
—
—
—
—
0
5
71
705
0
7
71
703
—
—
—
—
—
meloxicam; oral, parenteral, rectal
M01AC06 [21603965]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.99%
—
—
—
—
—
—
—
—
—
—
—
0
7
71
703
—
—
—
—
—
imidazoles/triazoles in combination with corticosteroids
D01AC20 [21601936]
6.7e-01
—
—
—
—
—
—
cases:8.45%
controls:4.51%
—
—
—
—
—
—
—
—
—
—
—
—
6
32
65
678
—
—
—
—
—
—
Excessive ear wax
H81 [2002000536]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.41%
—
—
—
—
—
—
—
—
—
—
—
0
10
71
700
—
—
—
—
—
Long-term monitoring of blood pressure
SPAT1100 [2001700201]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.70%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
71
705
—
—
—
—
—
—
Laparoscopic bilateral salpingo-oophorectomy
LAF11 [2001306444]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.99%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
71
703
—
—
—
—
—
—
Thorax X-ray examination
GD1AA [2001303617]
4.5e-01
1.5e+00
—
—
—
—
—
cases:12.68%
controls:8.45%
cases:9.86%
controls:2.39%
—
—
—
—
—
—
—
—
—
—
9
60
62
650
7
17
64
693
—
—
—
—
—
General health counselling
SPAT1312 [2001700413]
-1.6e-01
1.6e+00
—
—
—
—
—
cases:7.04%
controls:8.17%
cases:9.86%
controls:2.11%
—
—
—
—
—
—
—
—
—
—
5
58
66
652
7
15
64
695
—
—
—
—
—
Foot and toes X-ray examination
NH3AA [2001308267]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.99%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
71
703
—
—
—
—
—
—
Chronic asthma and similar chronic obstructive pulmonary diseases
203 [2001600201]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:2.11%
cases:0.00%
controls:0.70%
—
—
—
—
—
—
—
—
—
—
0
15
71
695
0
5
71
705
—
—
—
—
—
androstanolone
A14AA01 [21600917]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.85%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
71
704
—
—
—
—
—
—
Examination of postural anomaly
SPAT1213 [2001700314]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.83%
—
—
—
—
—
—
—
—
—
—
—
—
0
13
71
697
—
—
—
—
—
—
Treatment of reopened or infected surgical wound
SPAT1144 [2001700245]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.85%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
71
704
—
—
—
—
—
—
Epilepsy and comparable convulsive disorders
111 [2001600111]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.70%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
71
705
—
—
—
—
—
—
Cytomegalovirus IgM Ab [Units/volume] in Serum or Plasma
7853-5 [3015635]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.85%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
71
704
—
—
—
—
—
—
fexofenadine; oral
R06AX26 [21603525]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.85%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
71
704
—
—
—
—
—
—
Other primary gonarthrosis
M17.1 [45596493]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:4.08%
cases:0.00%
controls:1.55%
—
—
—
—
—
—
—
—
—
—
0
29
71
681
0
11
71
699
—
—
—
—
—
Occupational therapy
R4120 [2001310234]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.55%
cases:0.00%
controls:0.99%
—
—
—
—
—
—
—
—
—
—
0
11
71
699
0
7
71
703
—
—
—
—
—
valsartan and amlodipine
C09DB01 [21601842]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.99%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
71
703
—
—
—
—
—
—
Pain, unspecified
R52.9 [45544151]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.85%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
71
704
—
—
—
—
—
—
dutasteride; oral
G04CB02 [21602676]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.85%
cases:0.00%
controls:0.99%
—
—
—
—
—
—
—
—
—
—
0
6
71
704
0
7
71
703
—
—
—
—
—
Cholesterol [Moles/volume] in Serum or Plasma
14647-2 [3019900]
-3.1e-01
-6.9e-02
9.6e-01
—
—
—
—
cases:26.76%
controls:33.24%
cases:16.90%
controls:17.89%
cases:7.04%
controls:2.82%
—
—
—
—
—
—
—
—
19
236
52
474
12
127
59
583
5
20
66
690
—
—
—
—
Removal of fixed orthodontic appliance with at least 7 brackets
SJC50 [2001310435]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.85%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
71
704
—
—
—
—
—
—
Myalgia
M79.1 [45587062]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.69%
—
—
—
—
—
—
—
—
—
—
—
—
0
12
71
698
—
—
—
—
—
—
fluvastatin; oral
C10AA04 [21601859]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.27%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
71
701
—
—
—
—
—
—
Flat foot [pes planus] (acquired)
M21.4 [45586915]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.70%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
71
705
—
—
—
—
—
—
Acute laryngitis
J04.0 [45533538]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.85%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
71
704
—
—
—
—
—
—
testosterone; oral, parenteral, rectal, sublingual, transdermal
G03BA03 [21602510]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.99%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
71
703
—
—
—
—
—
—
tetracycline; oral, parenteral
J01AA07 [21602805]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:2.11%
cases:0.00%
controls:0.70%
—
—
—
—
—
—
—
—
—
—
0
15
71
695
0
5
71
705
—
—
—
—
—
Other specifed ventricular septal defect
Q21.08 [2000503268]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.70%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
71
705
—
—
—
—
—
—
Other and unspecified skin changes
R23.8 [45573020]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.27%
—
—
—
—
—
—
—
—
—
—
—
0
9
71
701
—
—
—
—
—
Counselling and guidance which enhance independent living
R2130 [2001310196]
1.6e+00
—
—
—
—
—
—
cases:7.04%
controls:1.55%
—
—
—
—
—
—
—
—
—
—
—
—
5
11
66
699
—
—
—
—
—
—
diclofenac; ointment
M02AA15 [21604051]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.99%
—
—
—
—
—
—
—
—
—
—
—
0
7
71
703
—
—
—
—
—
Polyuria
R35 [45539331]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.13%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
71
702
—
—
—
—
—
—
azelastine; nasal
R01AC03 [21605035]
—
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.99%
—
—
—
—
—
—
—
—
—
—
0
7
71
703
—
—
—
—
Fracture of tooth, open
S02.51 [45755762]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.27%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
71
701
—
—
—
—
—
—
Excision of other lesion extending through all layers of skin in head or neck
QAE10 [2001309784]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.13%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
71
702
—
—
—
—
—
—

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
42
179
4.11
8.36
2.9
2.1
2.72
2.73
mg/l
0.01
35
162
19
46
5.21
7.83
16.6
9.6
1.40
1.29
mmol/l
0.19
19
46
27
92
4.05
7.20
3.0
1.5
1676.05
1098.60
nmol/l
2.21
22
73
40
190
3.41
6.32
7.4
4.0
7.40
7.39
ph
0.55
29
138
27
100
3.68
6.30
2.2
2.3
2.29
2.37
g/l
0.24
27
94
23
79
3.77
5.95
12.1
8.0
105.26
103.49
mmol/l
0.37
23
79
32
137
3.35
5.91
7.4
5.0
—
—
—
0
0
21
70
3.79
5.65
16.8
7.5
7.40
7.42
ph
0.42
13
40
9
9
11.17
5.18
2.7
4.0
—
—
—
0
0
15
35
5.10
4.98
21.4
9.1
94.37
94.98
%
0.21
15
35
45
254
2.97
4.93
2.5
2.0
83.65
101.86
pmol/l
1.77
23
125
8
7
12.60
4.91
1.9
2.0
1.88
1.69
umol/l
—
8
7
47
278
2.89
4.61
18.9
11.4
1.12
1.19
inr
0.48
42
232
52
326
3.00
4.55
15.6
7.7
1.21
1.21
mmol/l
0.15
42
291
15
39
4.56
4.52
21.0
8.4
1.26
1.33
%
0.15
15
39
13
30
5.03
4.39
2.9
4.4
0.64
0.65
%
0.04
13
30
30
145
2.80
4.26
4.5
4.2
—
—
—
0
0
13
32
4.70
4.15
2.8
4.3
1.47
1.29
%
0.16
13
32
20
78
3.14
4.14
2.7
1.5
—
—
—
0
0
14
38
4.30
4.07
22.9
8.4
0.76
0.63
%
0.64
14
38
26
119
2.83
4.06
2.3
1.9
476.85
453.94
pmol/l
0.14
20
104
34
179
2.66
4.05
6.9
3.6
0.00
0.00
estimate
-0.00
11
66
16
55
3.44
4.03
5.6
4.9
24.71
24.17
mmol/l
0.20
16
55
18
67
3.23
4.01
19.9
8.0
—
—
—
0
0
10
19
5.91
3.99
21.8
5.4
25.12
24.79
mmol/l
—
10
19
8
11
7.99
3.97
2.4
7.4
51.16
57.10
%
—
8
11
36
198
2.59
3.90
1.7
1.4
8.01
0.83
u/ml
0.51
14
53
24
109
2.78
3.77
2.8
2.5
2.94
0.78
mg/l
0.88
17
97
49
319
2.59
3.64
9.2
6.4
1.97
2.89
%
2.74
49
307
49
319
2.59
3.64
9.3
6.4
0.54
0.67
%
0.85
49
307
35
197
2.47
3.53
4.1
2.8
—
—
—
0
0
40
240
2.45
3.51
9.6
6.7
—
—
—
0
0
49
324
2.52
3.45
9.3
6.4
8.76
8.58
%
0.21
49
313
34
192
2.43
3.38
2.9
2.2
—
—
—
0
0
49
327
2.48
3.33
8.4
6.3
59.24
55.80
%
0.94
49
319
15
56
3.11
3.29
2.7
3.9
0.44
0.74
%
—
8
19
49
330
2.44
3.22
9.2
6.4
26.87
29.87
%
1.08
49
322
14
52
3.09
3.09
2.5
3.9
0.14
0.56
%
—
7
16
40
253
2.26
2.96
7.8
3.8
45.73
38.22
e6/l
0.09
32
174
6
9
7.13
2.92
2.2
3.1
16.73
15.16
%
—
6
9
15
60
2.88
2.92
1.3
1.4
—
—
—
0
0
19
87
2.59
2.88
5.4
4.6
7.37
7.38
ph
0.31
12
52
52
372
2.34
2.80
17.7
5.1
6.98
6.44
mmol/l
0.33
52
354
7
14
5.40
2.80
1.6
1.5
21.06
19.19
ng/l
—
7
14
15
63
2.73
2.67
1.9
3.4
63.10
71.17
e9/l
—
10
43
5
7
7.55
2.59
2.6
8.9
10.02
9.74
%
—
5
7
11
39
3.13
2.47
6.4
3.6
—
—
—
0
0
6
12
5.33
2.45
1.5
7.2
92.10
88.16
%
—
6
12
12
47
2.85
2.41
7.2
3.1
—
—
—
0
0
5
8
6.60
2.41
1.0
3.6
36.80
32.00
pg
—
5
8
18
88
2.38
2.36
2.8
1.8
—
—
—
0
0
5
9
5.86
2.25
1.2
1.0
448.96
18.41
mu/l
—
5
9
34
220
2.01
2.21
3.6
4.0
22.95
35.29
ng/l
0.52
23
155
12
53
2.51
1.92
3.2
3.8
0.00
0.25
%
—
5
16
12
53
2.51
1.92
3.1
4.3
0.00
0.07
%
—
5
14
5
12
4.38
1.85
4.0
1.6
—
—
—
0
0
5
12
4.38
1.85
4.0
1.6
—
—
—
0
0
5
12
4.38
1.85
4.0
1.6
—
—
—
0
0
5
12
4.38
1.85
4.0
1.6
—
—
—
0
0
9
36
2.70
1.81
6.8
3.6
—
—
—
0
0
7
25
2.98
1.69
7.9
4.2
36.49
36.91
°c
—
7
25
6
20
3.17
1.61
1.7
1.2
0.22
0.24
g/l
—
6
20
46
353
1.80
1.61
6.5
3.6
0.00
0.00
estimate
-0.00
12
71
27
177
1.83
1.60
1.9
1.5
2.02
2.23
g/l
0.26
19
100
31
214
1.77
1.54
7.4
5.9
—
—
—
0
0
46
356
1.77
1.54
6.5
3.5
0.00
0.00
estimate
-0.00
12
67
6
22
2.87
1.46
1.7
1.1
1.18
1.18
g/l
—
6
22
45
351
1.72
1.42
6.6
3.5
0.00
0.00
estimate
-0.00
13
72
22
142
1.78
1.35
2.0
2.3
—
—
—
0
0
35
261
1.65
1.26
6.7
3.5
0.00
0.02
estimate
0.49
11
62
8
41
2.06
1.12
11.9
5.5
25.05
24.64
mmol/l
—
8
41
37
286
1.59
1.12
3.6
2.6
—
—
estimate
—
0
0
5
21
2.48
1.11
2.0
2.3
10.20
2.27
index
—
5
11
11
60
1.98
1.09
1.5
1.6
—
—
—
0
0
18
117
1.71
1.06
2.2
1.9
—
—
—
0
0
14
85
1.80
1.03
1.8
1.3
—
—
—
0
0
9
49
1.95
1.03
1.7
1.2
—
—
—
0
0
63
678
0.52
1.00
48.9
21.7
4.12
4.48
e12/l
5.52
63
662
63
678
0.52
1.00
48.7
21.6
30.51
30.05
pg
0.82
63
671
63
678
0.52
1.00
48.7
21.6
91.69
90.13
fl
1.25
63
671
63
678
0.52
1.00
50.1
21.8
122.46
133.88
g/l
6.96
63
671
63
678
0.52
1.00
48.9
21.8
7.17
6.56
e9/l
1.42
63
662
63
678
0.52
1.00
53.6
22.1
36.77
39.87
%
6.41
63
671
15
94
1.75
1.00
2.1
1.7
—
—
—
0
0
63
677
0.53
0.96
48.9
21.8
277.62
255.47
e9/l
1.57
63
663
36
293
1.45
0.78
6.1
3.3
6.52
6.25
ph
0.64
21
157
5
23
2.26
0.78
9.0
5.6
1.10
1.09
mmol/l
—
5
23
5
23
2.26
0.78
1.8
1.3
436.60
312.08
ug/g
—
5
13
7
40
1.83
0.74
1.0
2.3
2.49
4.14
ug/l
—
7
35
7
44
1.65
0.67
12.4
5.8
—
—
—
0
0
5
30
1.71
0.62
3.2
1.5
—
—
—
0
0
0
21
0.00
0.61
0.0
1.1
—
—
—
0
0
46
405
1.36
0.57
5.5
3.6
—
—
—
0
0
24
193
1.36
0.53
3.5
3.5
—
—
—
0
0
18
227
0.73
0.50
2.6
3.0
—
—
—
0
0
47
421
1.32
0.48
7.0
4.0
—
—
—
0
0
7
102
0.65
0.43
1.4
1.7
—
—
—
0
0
0
15
0.00
0.41
0.0
1.1
—
—
—
0
0
0
15
0.00
0.41
0.0
1.1
—
—
—
0
0
50
540
0.77
0.41
42.8
18.5
332.18
333.06
g/l
0.31
50
540
23
192
1.29
0.38
4.8
3.0
0.00
0.00
estimate
—
9
59
16
196
0.77
0.36
6.1
3.2
4.48
7.85
mmol/l
2.36
16
171
22
185
1.27
0.34
1.9
1.4
—
—
—
0
0
63
607
1.25
0.21
46.5
16.9
138.16
139.59
mmol/l
2.88
63
596
0
11
0.00
0.21
0.0
1.3
—
0.36
—
0
6
0
10
0.00
0.21
0.0
2.1
—
—
—
0
0
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
0
12
0.00
0.21
0.0
2.4
—
—
—
0
0
0
12
0.00
0.21
0.0
1.5
—
3.20
—
0
6
0
12
0.00
0.21
0.0
1.6
—
—
—
0
0
0
12
0.00
0.21
0.0
2.0
—
10.00
—
0
12
0
13
0.00
0.21
0.0
3.5
—
—
—
0
0
0
14
0.00
0.20
0.0
1.6
—
—
—
0
0
61
631
0.81
0.20
29.3
12.5
—
—
—
0
0
63
608
1.24
0.20
46.5
16.9
3.96
3.95
mmol/l
0.11
63
596
26
239
1.14
0.15
1.9
2.0
—
—
—
0
0
63
613
1.19
0.13
31.3
14.5
23.99
21.66
mg/l
0.36
57
492
5
63
0.78
0.08
1.4
1.6
—
—
—
0
0
12
133
0.88
0.08
3.0
5.9
2.02
1.97
ug/l
0.03
12
120
8
77
1.04
0.07
1.4
1.2
—
—
—
0
0
63
640
0.89
0.05
41.8
18.0
63.76
72.70
umol/l
1.34
63
632
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
4.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
4.8
—
—
—
0
0
0
7
0.00
-0.00
0.0
11.1
—
6.26
—
0
7
0
8
0.00
-0.00
0.0
1.9
—
107.25
—
0
8
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.9
—
3.85
—
0
8
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.9
—
1.22
—
0
8
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
15.2
—
15.68
—
0
5
0
5
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.3
—
0.89
—
0
9
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
8
79
1.01
-0.00
2.4
2.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
8.4
—
0.61
—
0
5
5
58
0.85
-0.00
1.8
1.4
—
—
—
0
0

Mortality – FinRegistry

↥

Association

Association between endpoint E4_MARASMUS and mortality.

Females

Parameter HR [95% CI] p-value
E4_MARASMUS 5.254 [2.49, 11.07] < 0.001
Birth year 0.996 [0.99, 1.0] 0.322

During the follow-up period (1.1.1998 — 31.12.2019), 120 out of 307 females with E4_MARASMUS died.

Males

Parameter HR [95% CI] p-value
E4_MARASMUS 6.144 [2.76, 13.69] < 0.001
Birth year 0.993 [0.98, 1.0] 0.122

During the follow-up period (1.1.1998 — 31.12.2019), 90 out of 242 males with E4_MARASMUS died.

Mortality risk

Mortality risk for people of age

years, who have E4_MARASMUS.

N-year risk Females Males
1 0.561% 1.389%
5 2.995% 8.042%
10 7.721% 19.488%
15 14.526% 35.354%
20 23.997% 52.914%

Relationships between endpoints

↥

Index endpoint: E4_MARASMUS – Nutritional marasmus

GWS hits: -

Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
loading spinner Loading data